WALTHAM, Mass.--(BUSINESS WIRE)--Novant Health has successfully partnered with Glytec to achieve best practice for insulin therapy in accordance with American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE) guidelines. Through a combination of Glytec’s FDA-cleared eGlycemic Management System® (eGMS®) and expert clinical change management program, Novant Health of Winston-Salem, North Carolina has now transitioned from manual, paper-based protocols for sliding-scale insulin therapy to fully integrated, computer-guided decision support for basal-bolus insulin therapy.
“We had 156 patients receiving basal-bolus insulin therapy through Glytec’s system the very first day of go live at Forsyth Medical Center, which is our health system’s largest facility,” says Dr. A.J. Patefield, senior vice president and chief medical information officer for Novant Health. “That number was much higher than projected. In fact, we were told it broke a record in terms of Glytec’s experience over the past six years with major health systems throughout the country. We’ve since gone live at all other Novant Health facilities and experienced great overall adoption.”
Dedicated Glytec and Novant Health project teams worked hand in hand to prepare the organization not only for the implementation of new technology, but also for the significant change in clinical practice. “Transitioning from sliding-scale to basal-bolus insulin is BIG,” explains Dr. Catherine A. Rolih, medical director of Novant Health diabetes service line. “Although we were very excited to go live with the Glytec system, we knew that eliminating a well-established practice like sliding-scale insulin would be challenging. However, Glytec provided us with great insights and strategies for overcoming the common barriers and achieving maximal utilization. They have proven to be an exceptional partner.”
Glytec’s proprietary SmartClick® technology for interoperability allows Novant Health care teams to access eGMS® directly from the Epic electronic health record, with single sign-on and patient in context. eGMS® also interfaces with lab, ADT and charting systems, enabling a streamlined workflow. The safety and efficacy of eGMS® has been validated by more than 60 clinical studies published in medical journals and presented at medical conferences around the globe.
“Glytec has demonstrated subject matter expertise in glycemic management, insulin therapy and workflow optimization,” adds Patefield. “They’ve taken a highly collaborative and flexible approach, which we truly appreciate, and we’ve had great results. I can definitely say that Glytec’s system is helping us deliver proactive, personalized care, which is our top priority.”
Glytec is the pioneer of personalized digital therapeutics, enabling best practices for inpatient and outpatient insulin optimization. The company’s patented and FDA-cleared software-as-a-medical-device solutions improve the safety and health of people with diabetes and make insulin a more effective medication option for the millions unable to achieve their treatment goals. Glytec combines evidence-based decision support technologies with expert clinical services to optimize insulin therapies in the hospital and at home, leading to reductions in hypoglycemia and other complications as well as avoidable ED visits, hospitalizations, readmissions and drug waste. The company has offices in Waltham, Massachusetts and Greenville, South Carolina. For more information visit www.glytecsystems.com.